Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel + Enzalutamide in mCRPC post-Abiraterone
NCT05627752Phase 3Recruiting
- Sponsor
- Zhongnan Hospital of Wuhan University
- Start
- Jun 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of enzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Zhongnan Hospital of Wuhan University. Started Jun 2024; status: recruiting.
02
Drugs
enzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05627752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05627752.